Pharmaceuticals

Global Huntington’s Disease Treatment Industry Insights: Key Trends and Growth Estimates

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the huntington’s disease treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Huntington’s Disease Treatment Market between 2026 and 2030?

The huntington’s disease treatment market size has seen rapid expansion in recent years. It is anticipated to increase from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. This historical growth can be linked to several factors, including the limited availability of treatment options for neurodegenerative conditions, an increase in the diagnosis of genetic neurological diseases, an initial emphasis on symptomatic management, the widening scope of neurology specialty care, and a rise in hospital-based neurological treatments.

The huntington’s disease treatment market is poised for substantial growth in the upcoming years, with projections indicating it will reach $1.48 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.6%. This expansion is primarily attributed to advancements in gene therapy technologies, a rise in investment dedicated to rare disease research, an increase in orphan drug designations, wider adoption of precision medicine, and an expanding pipeline of disease-modifying therapies. Noteworthy trends during this forecast period include an intensified focus on disease-modifying treatments, the growing acceptance of gene and RNA-based therapies, the broadened application of combination therapy approaches, a greater emphasis on developing drugs specific to symptoms, and an increase in clinical trial activities for rare neurological disorders.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Huntington’s Disease Treatment Market?

The Huntington’s disease treatment market is anticipated to expand due to the rising adoption of gene therapies. These therapies involve modifying or replacing defective genes to treat or prevent illnesses at a genetic level. Their growth is propelled by advancements in precision medicine, allowing for precise targeting of genetic origins and superior results compared to conventional methods. For Huntington’s disease, gene therapies work by deactivating the faulty HTT gene, which is responsible for producing harmful proteins, thereby preventing damage to nerve cells. This approach helps to decelerate disease progression, safeguard brain function, and holds promise for sustained management. As an illustration, a report from July 2023 by the American Society of Gene & Cell Therapy (ASGCT) and Citeline indicated that the number of gene therapies in phase II increased from 247 at the end of Q1 2023 to 260 by the end of Q2, representing a 5% rise. Consequently, the increasing prevalence of gene therapies is a significant catalyst for the growth of the Huntington’s disease treatment market.

How Is The Huntington’s Disease Treatment Market Organized Into Various Segments?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Competitive Trends Are Impacting The Structure Of The Huntington’s Disease Treatment Market?

Major companies within the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially enhance patient quality of life while slowing the progression of the disease. Selective VMAT2 inhibitor capsules are medications that block vesicular monoamine transporter 2, a protein involved in packaging neurotransmitters for release in the brain. These drugs help reduce neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For instance, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor, functioning by reducing excessive dopamine signaling in the brain to help control involuntary movements. The medication is available in multiple capsule strengths and can be taken with or without food, providing a convenient dosing option for patients.

Who Are The Major Companies Operating In The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Huntington’s Disease Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795